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12Supplemental material is available online.Video clip is available online.There are 2 concepts regarding the nature of recovery when
arterial blood supply is interrupted to create ischemia and
then followed by returning blood flow or reperfusion. First,
many think that ischemia itself is the detrimental factor,
and the only role of reperfusion is to inflict the ‘‘coup de
grace.’’ This report suggests that ischemia creates a progres-
sive chaos in the physiologic components responsible for
retaining cellular architecture that may produce structural
and metabolic cell destruction, which has been defined
extensively by in-depth reviews.E1,E2 Vulnerability to such
damage after returning flow may become accelerated by
reperfusion with normal blood or modified by control of
the reperfusate process. The importance of controlled
reperfusion is based on conclusions derived from data
evolved during the past 35 years of our investigations of
this process.
The ischemic time responsible for tissue death or necrosis
is uncertain in different organs, but this interval is not fixed
only by the time of interruption of blood supply.1 Experimen-
tal and clinical application of modifying the reperfusion
process in the heart, lung, extremity, and brain demonstrate
that control of the conditions and composition of the reperfu-
sate process exert a profound effect on ultimate necrosis and
fosters recovery.2-7, E3,E4Moreover, further understanding of
the metabolic changes during ischemia may allow tailoring
of even more coordinated reperfusion approaches to
address the evolving metabolic processes responsible for
this injury. Advocates of control of the reperfusion state
appreciate the uncertainty of the duration of time that
becomes responsible for necrosis and understand there may
be a blend of irreversibility (unavoidable damage despitem the Division of Cardiothoracic Surgery, David Geffen School of Medicine at the
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The Journal of Thoracic and Cardiovascular Surgereperfusion), coupled with a vulnerability to necrosis that
reperfusion can either accentuate (if normal blood is
delivered) or reverse if given in a controlled way.CURRENT DILEMMA
The spotlight is nowon the duration of ischemia and how to
minimize its consequences when blood supply is interrupted,
and uses methods such as hypothermia to limit damage in or-
gans that now extend from heart to brain.E5,E6 For those who
focus only on ischemia, their primary objective is to determine
how quickly to reperfuse, rather than addressing the quality of
the reperfusate. Techniques are not considered if they delay
the central objective of very rapidly introducing reperfusion
with unmodified regular blood. This ‘‘when, rather than
how’’ concept after prolonged ischemia disregards evidence
that controlled reperfusion successfully alters reflow
damage in the heart, lung, extremity, and brain.2-7,E3,E4
An analogy that improves focus on reperfusate control is
the correlation of the ischemia/reperfusion process with the
concept of entropy, a process that comprises a biologic phe-
nomenon of progressive disunity during ischemia and then
accelerates such disorganization of normally coordinated
mechanical and physiologic activities when normal blood
supply is suddenly restored.
I will initially put these concepts into perspective with ex-
perimental and clinical data in the 4 organ systems (heart,
brain, lung, and extremity) that have been tested. This re-
gional approach sets the stage for introducing a biologic
phenomena of global controlled perfusion that applies to
the whole body and for addressing regional organ systems
(eg, kidney and liver) that have not yet been evaluated.
Toward that end, we have also profited from our prior work
on reoxygenation after cyanosis, as occurs with congenital
heart disease. The Journal of Thoracic and Cardiovascular
Surgery recognized the importance of these issues and ad-
dressed them in supplements in 19868 and 1995.9 Reoxyge-
nation damage was markedly limited and benefit was
achieved by regulating the conditions of reflow delivery
and blood composition components.E7-E9 There is
commonality in that the basic issue identifies that focus
should not be on how quickly to reperfuse, but rather to
identify how to reperfuse in a manner that controls reflow
conditions (ie, flow, temperature, pressure, mechanical
behavior) and composition (ie, a cocktail that addresses
different metabolic pathways) to actively salvage the cell
population that did not become necrotic during the
ischemic interval.ry c July 2010
Buckberg Expert CommentaryAbbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
CPR ¼ cardiopulmonary resuscitation
WBC ¼ white blood cellINSIGHT INTO MODIFIED ELEMENTS DURING
CONTROLLED REPERFUSION
Disrupted metabolic processes and structure after sudden
post-ischemic reintroduction of regular blood supply was
termed the ‘‘double-edged sword’’ by Braunwald and Klo-
ner,E10 because ‘‘reperfusion injury’’ may accentuate dam-
age beyond that caused by ischemia. From my perspective,
the disorganized cellular mechanism debris reflects ‘‘shrap-
nel’’ after a bomb explosion, which contains innumerable
fragments that become dislodged from normality. The col-
lective presence of this spectrum of disrupted elements
keynotes the impossible task that confronts selection of
any single treatment option that is earmarked to achieve
the fundamental goal of rebuilding functional normality by
globally remedying reperfusion damage. There is no magic
bullet to prevent failure of any individual treatment, al-
though several reperfusion components have been success-
fully used to restore near-normal function after prolonged
ischemia. Simultaneously, these positive findings become
balanced by recognition that they only begin to sort out
the facts. The future requires blending these successful first
steps with the evolving reperfusion injury management
option expansion.E1,E2
My reperfusion injury approach started in 1975,10 when
John Kirklin at the University of Alabama told me that sud-
den myocardial thickness and palpable rigidity developed
immediately after removing the aortic clamp after internal
thoracic artery grafting. This observation initiated my ques-
tioning of the role of calcium in this injury.10 This inquiring
process continued, and the subsequently evolved compo-
nents of the ‘‘reperfusion cocktail and its delivery method’’
address several factors that are disrupted by simply restoring
regular blood, which will otherwise accentuate the entropy
induced by ischemia. Current intervention applications in-
clude (1) lowering ionic calcium content, because unabashed
calcium infiltration disrupts the capacity to use oxygen and
accentuates structural changesE11,E12; (2) keeping the
contractile apparatus (in the heart) stopped with potassium
to reduce the demands for oxygen,E13 which simulates the
suggestion to rest in bed to aid recovery; (3) reducing cell
swelling with drugs (mannitol) to avoid edema that in turn
limits ionic and mechanical functionE14; (4) adding ions,
such as magnesium, to improve metabolism and limit cal-
cium entry11; (5) supplying metabolic fuels, such as glucose
and amino acids (glutamate and aspartate), to enhance
metabolic recovery, because these elements are lost duringThe Journal of Thoracic and Cischemia and replacement is needed to speed the recovery
process12; (6) limiting white blood cell (WBC) infiltration
by filters to avoid the temporary accentuation of damage
caused by these cells getting stuck to the capillaries, obstruct-
ing them, and simultaneously causing generation of toxic ox-
ygen products after reperfusion13; (7) adjusting blood acid-
base balance (pH) to allow the reperfused cells to metabolize
in the best environment, as well as supplying a buffer for the
toxic acid products that develop during ischemia and retard
recovery14,15; (8) supplying chemical agents or drugs to
combat offshoots of damage oxygen radical scavengers,E15
calcium antagonists,E16 and vasodilator agentsE4 that combat
the tissue disruption resulting from cell swelling; (9) limiting
the partial pressure of oxygen supply (from 400 mm Hg to
80–100mmHg) to reduce generation of destructive superox-
ide radicalsE17; (10) adjusting blood pressure during reperfu-
sion to preventmassive cell swelling that developswhen new
blood is supplied to areas whose blood vessel surface lining
is temporarily damaged.16 This maneuver limits subsequent
fluid leakage that further disrupts architecture and function.
Simultaneously, provision of an adequate perfusion pressure
is essential to ensure adequate flow distribution to deep and
superficial tissue within reperfused organs; (11) controlling
temperature to optimize the environment for repair; a balance
exists because normothermia accentuates nourishment,E18
whereas hypothermia attenuates damage because metabo-
lism is reduced by 50% with each 10C lowering of temper-
ature17,18; and (12) using regional pumps to control the
pressure and its dynamics to afford either pulsatile or
nonpulsatile delivery. Such regional delivery avoids
interventions that may change body blood pressure during
efforts to address single region recovery.
With increasing knowledge, the synergy of supportive
agents will expand to create an even more efficacious reper-
fusion and composition interface, building on current
knowledge to develop a fuller and more cohesive controlled
reperfusion process after ischemia.
CURRENTAPPLICATIONS OF CONTROLLED
REPERFUSION
Heart
Cardiac surgery. Cardiac procedures (1,000,000/year
worldwide) require a quiet heart to allow surgeons to do
a precise job. This requires producing ischemia by shutting
off the cardiac blood supply and subsequently sets the stage
for a reperfusion injury during every heart surgery proce-
dure. Our work established the use of blood cardioplegia
to limit the development of reperfusion injury to try to offset
this damage,19 and this method is now used in approxi-
mately 80% of hospitals worldwide. Of equal importance,
understanding its limitations to completely prevent ischemic
damage has led to our development of applying a warm-
blood cardioplegic reperfusate (delivered before restoring
normal blood flow) to offset this injury. This strategyardiovascular Surgery c Volume 140, Number 1 13
Expert Commentary Buckbergintroduced the controlled reperfusion concept12,E18,E19 and
is now used in approximately 50% of centers worldwide.
Its clinical background was initiated by John Kirklin’sE20
1988 report on the ‘‘science of cardiac surgery,’’ which
compared 2351 patients receiving controlled reperfusion
with 3872 patients receiving normal blood reperfusion and
demonstrated how it reduced mortality after 70 minutes of
aortic clamping.
The cost-savings aspect of this approachwas defined at the
Cleveland Clinic,E21 where application of the cardioplegic
method defined by our studies saved $2100 per patient ver-
sus less-expensive crystalloid techniques, resulting in
a $10,000,000/year cost salvage at that center. Moreover,
the report stated that this would translate to a $680,000,000
cost savings in 1992 (400,000 procedures in the United
States), and even more savings would exist if today’s cost
standards were applied.
That early report did not address changes in septum func-
tion as described next. The septum component of heart archi-
tecture must be considered because a) this structure occupies
approximately 40% of ventricular muscle mass,20 yet de-
spite this observation b) septum damage has been considered
an ‘‘expected complication’’ of cardiac surgery.E22-E26
Our integrated blood cardioplegic approach,18,E27 which
prevents the temporary and sometimes permanent loss of
the ventricular septum function, has not yet been applied
to this ongoing complication of conventional myocardial
protection methods.20 Other treatment approaches may be
equally effective, but verification of their protective capacity
value requires pre- and postoperative comparison of septum
function measurements when they are used. The presence of
normal function/structure relationships is essential for
proper septum performance, so that development of strate-
gies to prevent septum dysfunction is linked to understand-
ing this fundamental interaction.20
Structurally, the oblique fiber orientation of septum
muscle fibers results in the required twisting function needed
for efficient right ventricular ejection against increased pul-
monary vascular resistance; right ventricular failure results
from inadequate septum contractile performance.E28 A grad-
ing score by echocardiogram existsE29 and is commonly used
to define the extent of septum damage that ranges from mild
to severe hypokinesia, to akinesia, and finally to paradoxical
bulging like an aneurysm. Septum malfunction is caused by
stunning, yet this complication has been considered an
expected heart surgery outcome.E22-E26 Justification of this
commonly held conclusion is linked to the absence of
clinical problems when pulmonary vascular resistance is
low, as usually occurs in low-risk patients after coronary
bypass procedures. Conversely, a recent report of approxi-
mately 3300 patientsE30with preoperative normally contract-
ing septum demonstrated paradoxical septum dysfunction in
approximately 40% of patients, increasing to 60% after
valve procedures. Septum injury was thought to be related14 The Journal of Thoracic and Cardiovascular Surgeto the duration of aortic clamping; most important, there
was no report of the diminished functional that results from
lesser grades of damage. Conversely, our recent studies eval-
uated each aspect of septum function in a cohort of 119 con-
secutive patients. We used the integrated blood cardioplegia
method, which addresses correct delivery of myocardial
protection methods, and showed septal stunning is com-
pletely avoided despite aortic clamping intervals extending
to 157 minutes.20
These findings imply that maintenance of septum function
should become the barometer of myocardial protection to
determine adequacy of the method used, with recognition
that its damage is related to an avoidable reperfusion injury.
Septal damage also follows procedures without cardiople-
gia, such as coronary procedures without extracorporeal
circulation.E30 Cardiac manipulation during non-bypass pro-
cedures likely compromises septum nourishment when hy-
potension is caused by mechanically altering cardiac
position. Guidelines for subsequent treatment must use this
knowledge of septum injury to a) recognize and evaluate
this preventable dilemma, b) maintain any current technique
when septum damage is avoided, or c) change approaches if
septum damage is present.
ACUTE MYOCARDIAL INFARCTION
Aside from improving the results in open surgery, as re-
ported by the Cleveland Clinic several years ago, these reper-
fusion solutions have been shown to allow survival of heart
muscle involved in heart attacks (1,500,000 events in the
United States per year) by applying the only valid guideline
of gauging their capacity to return function of ischemic mus-
cle that has suffered up to 6 or more hours of no blood sup-
ply.2,E3 Verification of this functional end point is critical
because it addresses the currently misguided conclusion
that viability without function is a satisfactory result.
Unfortunately, treatment that provides only an open vessel
that now supplies an akinetic muscle reflects the wrong
results; this nonfunctional segment leads to subsequent heart
failure if its size exceeds 20% of left ventricular muscle
mass.E31,E32 Development of this noncontractile or akinetic
muscle after reflow with normal blood is evident from
experimental reports of myocardial cell death after
replacement of regular blood after 2 hours of ischemia.4 The
clinical model for this end point exists in the population with
acute myocardial infarction, because current methods of ur-
gent emergency angioplasty only restore normal blood reper-
fusion, without consistently demonstrating regional muscle
recovery. In many instances, angioplasty successfully opens
the coronary lumen to provide blood supply, but such reflow
is delivered to damaged myocardium that cannot resume
function if more than 50% of its mass is necrotic.E33 Stated
more simply, ‘‘the heart is a pump, not a highway map.’’
The infrastructure for controlled reperfusion was estab-
lished by our experimental studies that delivered controlledry c July 2010
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The Journal of Thoracic and Cardiovascular Surgery sup-
plement published in 1986 addressed this issue.4,8,E3,E13
These experimentally developed outcomes were then
transposed toward early clinical application, and the results
confirmed these findings by demonstrating remarkable
functional recovery of muscle in patients with more than 6
hours of myocardial infarction.2 Subsequent clinical applica-
tion of controlled reperfusion by an international cohort in
156 patients undergoing approximately 6 hours of ischemia
(ranging from 2–24 hours)4 were evaluated by echocardio-
gram or left ventriculogram studies before discharge, dem-
onstrating recovery of substantial regional function in
87% of patients with previously ischemic muscle.
Controlled reperfusion is the keynote management issue,
rather than focusing on who (surgeon or cardiologist) de-
livers this treatment. These baseline clinical observations
led to our 1986 suggestion of future development of
methods to introduce controlled reperfusion in the catheter-
ization laboratory rather than in the operating room.21 The
offshoot is the potential to initiate less-invasive warm reper-
fusion methods in selective patients, an endeavor that may
markedly broaden delivery of warm controlled reperfusion
to the vast population of patients with myocardial infarction.
The importance of restoring contractile function after acute
myocardial infarction has enormous implications. Current
cardiology and surgical management only restores normal
blood flow by using the concept of ‘‘how quickly to open
newblood supply,’’ rather than ‘‘how toproperly employ con-
trolled reperfusion.’’ Consequently,muscle loss occurs, as the
revascularized bulging ischemic segment simply becomes
akinetic.E32 This architectural event is caused by salvaging
the epicardium segment rather than rescuing transmural mu-
scle.E34 This current cardiology end point reduces mortality
and slows remodeling,E35 but retains an akinetic segment
(that exists when> 50% of muscle is irreversibly dama-
ged)E33 and sets the stage for subsequent progressive cardiac
dilation in the 20% of patients whose end-systolic volume in-
dex exceeds 40 mL/m2.E36,E37 Unfortunately, normal blood
reperfusion creates the structural surrogate for subsequent
development of congestive heart failure.our greatest health
risk. Conversely, controlled reperfusion offsets this hazard
and may have a major health care impact. In its simplest
form, inadequate treatment of acute myocardial infarction
reflects the primary therapy failure, because later ventricular
dilation leading to congestive heart failure becomes
a potentially avoidable secondary complication that stems
from the conventionally used regular blood reperfusion
approaches to treat acute myocardial infarction.
THE LAZARUS SYNDROME—SUDDEN DEATH
MANAGEMENT
A fascinating recent application of this controlled reperfu-
sion technology was described by our report of using theseThe Journal of Thoracic and Csolutions to treat sudden death after witnessed arrest, where
conventional in- and out-of-hospital survival is approxi-
mately 10%E38-E41 and approximately 33% of survivors
have permanent brain damage.E42 The nidus was our exper-
imental studies (in a model of left anterior descending artery
occlusion and circumflex artery stenosis) that showed near
complete cardiac recovery after 2 hours of intractable ven-
tricular fibrillation. This cardiac end point was achieved by
using a management protocol whereby (1) cardiopulmonary
resuscitation (CPR) was performed for 2 hours with effective
compressions aimed at achieving high systemic perfusion
pressure to ensure brain blood flow; (2) cardiopulmonary
bypass (CPB) was introduced via the femoral vessels with
the intent to (a) support the systemic circulation that became
distributed to the brain and other regions, while (b) simulta-
neously allowing cardiac catheterization studies to diagnose
the responsible cardiac lesion causing intractable ventricular
fibrillation; and (3) performing controlled reperfusion of the
underlying cardiac lesion in the same fashion described for
treating acute myocardial infarction.
These concepts were then clinically performed by appli-
cation in centers in the United States and Europe, where
36 patients underwent CPR for approximately 72 minutes
(range, 20–150 minutes).E43 Each patient had similar treat-
ment that included a) CPR to support the brain blood flow
with a monitored CPR systolic blood pressure of 60 mm
Hg; b) determination of the cardiac cause of the sudden
death in the catheterization laboratory, sometimes with per-
cutaneous body support with a heart–lung machine to sup-
port the body, and c) remedy of the cause of sudden death
by providing controlled reperfusion during coronary bypass
grafting.
This treatment strategy led to 80% survival and only 6%
neurologic damage, findings that dramatically differ from
those of conventional approaches. Moreover, normal heart
function was restored because ejection fraction at discharge
exceeded preoperative values in 13 of 14 patients who had
undergone pre-sudden death cardiac catheterization to docu-
ment underlying coronary anatomy and functional perfor-
mance.22 Immediate postoperative cardiac functional
recovery among these 36 patients was similar to that
achieved routinely after conventional cardiac procedures.
Furthermore, investigators in Japan,E44 Taiwan,E45 and Ko-
reaE46 recently studied sudden death and used only the CPB
and regular blood (or uncontrolled) reperfusion components;
cardiac survival improved to 30% after their initiating percu-
taneous bypass after sudden death, followed by standard an-
gioplasty. However, their overall approaches and results
differ from our method, because they did not use controlled
reperfusion or ensure ventricular venting. Myocardial
infarction-related myocardial necrosis was not avoided,
and their outcomes included stunning of remote muscle to
further diminish post-reperfusion cardiac performance. The
consequent low output state limited brain reperfusion andardiovascular Surgery c Volume 140, Number 1 15
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mately 50% of survivors. Their end points were ‘‘saved
the heart, but lost the brain,’’ and several collaborative cen-
ters in Japan are now planning to test our approach to deter-
mine if their findings are in agreement with our prior
report.E43 If confirmed, controlled reperfusion may become
the benchmark for new sudden death treatment strategies
that can avoid the current grim prognosis.
BRAIN ISCHEMIA: GLOBAL AND REGIONAL
APPLICATION
The biologic importance of introducing controlled reper-
fusion to ‘‘save the brain and heart’’ after prolonged total
brain ischemia has multiple settings, including (a) deep hy-
pothermic circulatory arrest during cardiac surgery of infants
and adults; (b) sudden death without cardiac cause, as in
drowning of children; and (c) unwitnessed arrest after sudden
death. The extremely adverse effects of unwitnessed arrest
are well defined clinically, because recovery is approxi-
mately 1% and severe brain injury is nearly universal.
Such delays also exist during cold circulatory arrest during
cardiac surgery, because ischemic times are usually restricted
to less than 45 minutes to limit reperfusion brain damage.23
In contrast, successful application of controlled whole-
body reperfusion was experimentally documented after 90
minutes of deep hypothermic circulatory arrest,23 a manage-
ment strategy used in infants with congenital heart disease,
as well as in adults undergoing great vessel procedures.
The prime of the heart–lung machine was adjusted with ad-
ditives so that it became a controlled reperfusate delivered
immediately after 90minutes of deep cooling. This approach
offset the reperfusion damage resulting from regular blood
reperfusion and markedly improved cardiac, hepatic, pulmo-
nary, and brain recovery.23 Recent studies24 also showed
that substituting a controlled reperfusate prime for the regu-
lar blood reflow after 15 minutes of unwitnessed normother-
mic arrest for 15 minutes (ventricular fibrillation without
ventilation) allowed complete neurologic recovery in 6 of
7 pigs to supplement evidence of the validity of the global
concept of controlled reperfusion (Video 1). In contrast,
severe brain damage followed regular blood reperfusion
on bypass, despite salvage of cardiovascular function.
Remarkable implications follow this observation, because
CPR after unwitnessed arrest may cause marked reperfusion
damage that may be avoided by controlled reperfusion. Con-
sequently, further studies are required to introduce the ap-
propriately delayed time intervals needed for peripheral
CPB cannula placement after encountering patients with un-
witnessed arrest. The required time interval suggested by re-
cent reports show extracorporeal circulation implemented
within 15 minutes in patients with sudden death undergoing
witnessed arrest will improve results by achieving 30% sur-
vival.E44,E46 To address this need, a new model of brain
death was developed to study 30 minutes of totally absent16 The Journal of Thoracic and Cardiovascular Surgebrain flow without CPB. This novel approach accounted
for the 15-minute delay for canula insertion and also
excluded the secondary CPB complications (release of
mediators from other organs and inflammation alterations)
to allow better understanding of brain ischemia. The
severe brain damage that follows normal blood reperfusion
after 30 minutes was avoided; 3 of 6 animals recovered
normal neurologic function (Video 2), and the other 3 sub-
jects demonstrated minimal injury at 48 hours.E47 This com-
plete neurologic recovery after 30 minutes of total brain
vascular occlusion totally contradicts traditional conclu-
sions that imply irreversible brain damage follows only
5 minutes of no brain blood flow.
More important, these findings of complete brain recov-
ery after 30 minutes of no brain flow were achieved by ap-
plying peripheral perfusion methods that may be applied
to stroke victims. Regional reperfusion methods via cannu-
lation of peripheral vessels exist, so that a combined
blood-based reperfusate condition and composition ap-
proach may be developed in a manner that uses a patient’s
own blood. Consequently, such percutaneous observations
may open the door to subsequent study of regional ischemia
during stroke, a major worldwide health care hazard.
PULMONARY ISCHEMIA AND
TRANSPLANTATION
Lung ischemia/reperfusion injurywas studiedbydeveloping
an in vivomodel to simulate the clinical transplant setting used
by Halldorsson and colleagues6,E4 and Allen,E48 which was
derived from our earlier collaborative analysis of controlled
heart reperfusion.4,E3 Results after 2 hours of warm left lung
ischemia were compared after (a) uncontrolled reperfusion
with normal blood, (b) uncontrolled reperfusion with WBC
filtration, (c) controlled reperfusion with a modified solution,
and (d) modified solution and WBC filtration. The severe
lung injury characterized by a marked increase in pulmonary
vascular resistance decreased, altered compliance, increased
lung water, and minimized alveolar capillary damage by
using either a modified solution or WBC filtration alone. In
contrast, both use of a modified solution and WBC filter to
prevent reperfusion injury essentially avoided these adverse
alterations, as there was no change in pulmonary compliance,
lung water, or alveolar capillary function, and pulmonary
vascular resistance was only slightly increased. 6,E4
Of equal importance, the contralateral right lung also sus-
tained the secondary effect of an unanticipated injury after
uncontrolled reperfusion of the ischemic left lung; this dam-
age was prevented by controlled WBC free reperfusion of
the ischemic lung. This finding documents that reperfusion
injury metabolic by-products play a significant role in con-
tralateral lung damage and that controlled reperfusion pre-
vents this secondary injury.
Translation of these short-term studies into the area of
clinical lung transplantation was then accomplished byry c July 2010
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under hypothermic conditions, and results were almost
identical to the findings after 2 hours of warm ischemia.6,E4
The severe pulmonary reperfusion injury after uncontrolled
(normal blood) reperfusion after 24 hours of cold lung
ischemia was almost completely avoided by the controlled
(WBC and modified) reperfusion solution, because near
complete pulmonary function recovery occurred.E4 These
experimental findings became the infrastructure for clinical
studies by Lick and associatesE49 (who validated their
importance) and Schnickel and associates,E50 who used
these methods at the University of California at
Los Angeles in more than 100 lung transplants. Translation
of experimental findings in clinical lung ischemia/reperfu-
sion studies closely mirrors the previous cardiac and
brain observations that document controlled reperfusion
effectiveness.
Similar lung reflow problems also confront pediatric and
adult patients who undergo open surgery because the pro-
cess of lung ischemia/reperfusion routinely occurs during
and after extracorporeal circulation. Development of respira-
tory distress syndrome may follow a successful cardiac op-
eration, because noncardiac lung congestion may occur and
initiate pulmonary problems, which prolongs intensive care
area hospitalization and may become fatal. Potential expan-
sion of this approach by applying a specialized pulmonary
delivery method, together with a solution that resembles
our cardiac solution without added potassium (because the
lung does not beat), may open new research arenas. Cer-
tainly, the large number of high-risk adults who might
have lung reperfusion injury during CPB exist, as they ac-
count for approximately 40% of the 1,000,000 worldwide
cardiac operations.
LOWER EXTREMITY
Reperfusion after acute loss of peripheral leg circulation
(from either thrombosis or embolism) may lead to a massive
reperfusion injury that is life threatening when toxic prod-
ucts that accumulate during ischemia are released after
reflow. Furthermore, the leg with new blood flow may be-
come congested and develop post-reperfusion severe edema
and contracture, which normally result in leg amputation.
Application of the concept of controlled reperfusion of is-
chemic limbs was carried out in initial experimental studies
in Germany by Schlensak and colleaguesE51 and Beyersdorf
and colleaguesE52 and then applied clinically. The infrastruc-
ture of this understanding began in the 1980s during our
collaborative cardiac studies.25,E53 Minor modifications of
the cardiac warm-extremity reperfusate were made (eg, no
potassium was added to simulate the lung study approach),
and results after 6 hours of lower-extremity ischemia were
compared with those after normal blood reperfusion. Con-
trolled reperfusion resulted in complete leg salvage, together
with recovery of normal vascular resistance, minimalThe Journal of Thoracic and Ccreatine phosphokinase release, negligible efflux systemic
potassium build-up, normal recovery of glucose and oxygen
consumption, and limited edema formation.E52,E54
These baseline experimental observations became the
keynote to initial clinical studies in 12 patients with clinical
contracture after prolonged ischemia.5 Contracture was re-
versed when the regional warm reperfusate was delivered
by mixing the designed chemical solution with the recipi-
ent’s own blood; all legs were salvaged with recovery of nor-
mal function in most. These findings were compared with
the adverse outcomes in 1213 cumulative patients evaluated
from literature review.E54,E55
Moreover, these reproducible early observations led to the
current ongoing European clinical study to determine how to
treat patients with acute extremity ischemia after they seek
medical advice. In addition, this preventable complication
of extremity reperfusion injury may be avoided by clinically
implementing this controlled reperfusion strategy after a)
prolonged femoral cannula insertion during extended CPB
procedures or extracorporeal perfusion for cardiac support,
and b) longer intervals with intraaortic balloon counterpulsa-
tion support. If successful, controlled reperfusion would re-
place amputation for this patient cohort.
Ramifications of reperfusion damage may also assume
importance after vascular surgery for obstructive femoral
popliteal disease. Subsequent testing of controlled reperfu-
sion (using a patient’s own blood mixed with the solution)
may be compared with normal blood reperfusion; results
will determine whether early leg swelling and prolonged
hospitalization after lower-extremity revascularization are
minimized. If so, then controlled reperfusate delivery may
broaden management options for this currently unrecog-
nized vascular surgery reperfusion injury complication.
OTHER APPLICATIONS
The aforementioned experimental and clinical applica-
tions to the heart, brain, lung, and extremity reflect the open-
ing act to a novel concept linked to appreciation that
controlled reperfusion reflects a biologic phenomena that
mandates revision of current concepts based on conventional
ischemia time frames thought to cause ultimate organ death,
a concept that is not currently related to varying the mecha-
nisms of reperfusion. The yardstick of studied organs may
expand to address renal, hepatic, and gastrointestinal organs
that either undergo transplantation or are subject to ischemic
intervals during operative procedures needed for their repair.
Moreover, multiorgan failure evolves in patients in shock
when normal blood reperfusion causes a low output syn-
drome. Gearing a reflow approach that takes advantage of
principles emerging from both regional and global studies
may innovate novel strategies that offset current reperfusion
damage when only regular blood is used. Although clinical
teams exist to deal with such regional and global ischemia
events, they currently do not recognize (a) the potentialardiovascular Surgery c Volume 140, Number 1 17
Expert Commentary Buckbergrole of reperfusion control or (b) their subsequent charge to
develop creative ways to implement this treatment.
CONCLUSIONS
Reperfusion injury is a biologic event, and the complica-
tions of simply returning regular blood can be offset in the
heart, brain, lung, and extremity by administering a con-
trolled reperfusate that alters reperfusion conditions (ie, pres-
sure, flow, temperature) and composition (ie, ionic content,
nutrients, acid-base balance). Such a reperfusion strategy
returns function to organs that would otherwise develop
necrosis if only regular blood was restored.
Future application of controlled reperfusion may include
the brain, kidney, liver, and whole body. The biologic nature
of reperfusion injury, together with experimental and clini-
cal effectiveness in the heart, lung, extremity, and brain, im-
plies that controlled reperfusion after ischemia may become
a unifying recovery denominator that will lead to new im-
proved results in a large number of patients whomay recover
from periods of ischemia durations that are now thought to
be irreversible.
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